Indication
fallopian tube
9 clinical trials
15 products
1 drug
Clinical trial
A Multicenter, Single-arm, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokenetics of RC88 Monotherapy in Platinum-resistant Reccurent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal CancerStatus: Not yet recruiting, Estimated PCD: 2026-06-30
Product
RC88Clinical trial
Phase 1b/2a Study Investigating ATX-101 in Combination With Platinum-based Chemotherapy in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube and Primary Peritoneal CancerStatus: Terminated, Estimated PCD: 2023-11-30
Product
ATX-101Clinical trial
A Pilot Study of Nivolumab With or Without Ipilimumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Product
Carboplatin + PaclitaxelProduct
NivolumabProduct
IpilimumabClinical trial
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CTStatus: Recruiting, Estimated PCD: 2025-06-01
Product
[18F]FluorThanatraceClinical trial
Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are Folate Receptor α PositiveStatus: Recruiting, Estimated PCD: 2026-05-31
Product
Mirvetuximab SoravtansineClinical trial
TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2027-02-02
Product
Paclitaxel + BevacizumabClinical trial
Oregovomab and Non-platinum Chemotherapy in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment: a Multicenter, Two-cohort, Single-arm Phase 2 TrialStatus: Recruiting, Estimated PCD: 2024-05-01
Product
Orevogomab+PLDProduct
Orevogomab+PaclitaxelClinical trial
A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior TherapiesStatus: Completed, Estimated PCD: 2022-02-28
Product
EnzalutamideClinical trial
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine or NY-ESO-1 Overlapping Peptides Vaccine in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater RemissionStatus: Completed, Estimated PCD: 2023-04-06
Product
WT1Drug
T-VECProduct
NY-ESO-1 Vaccine